236 results about "Injections subcutaneous" patented technology

The invention discloses a subcutaneous injection site detection and recommendation system based on an intelligent algorithm, and aims to improve the safety of long-term subcutaneous injection and the drug absorption efficiency and reduce the risk of related complications such as subcutaneous hemorrhage, subcutaneous induration and subcutaneous fat hyperplasia at the same time. Comprising a subcutaneous tissue detection module for acquiring subcutaneous vascular distribution, fat layer thickness and induration state of a target part through infrared imaging and ultrasonic technologies and generating subcutaneous tissue characteristic data; the data processing module analyzes the feature data by using an image recognition algorithm, and recognizes a blood vessel dense region, induration and a part where fat hyperplasia has occurred; the injection part recommendation module is used for evaluating an analysis result of the data processing module based on a machine learning algorithm in combination with personalized injection historical data of the patient, and generating an optimal injection part recommendation scheme avoiding a risk area; the intelligent imaging and data analysis technology is utilized, the subcutaneous injection part selection accuracy is improved, and the patient comfort and the treatment effect are improved.

The invention discloses a semaglutide soluble microneedle patch composition. The soluble microneedle patch composition comprises a needle body material and a backing layer material, the material of the needle body can be only composed of a high-concentration semaglutide solution. According to the semaglutide micro-needle patch, the drug loading capacity of semaglutide in the micro-needle patch can be greatly improved, the hypoglycemic effect which is the same as that of subcutaneous injection administration can be achieved under the same administration amount, and a new dosage form choice is provided for the pharmaceutical application of semaglutide, such as hypoglycemic weight reduction and the like.

The invention relates to the technical field of medical instruments, in particular to a hypodermic injection device which comprises a pen body, an insulin refill detachably connected to the bottom of the pen body, and a disposable pen needle matched with the bottom of the insulin refill. The push rod is movably arranged in the pen body, and the bottom end of the push rod is used for pushing liquid medicine in the insulin refill; a labor-saving assembly is mounted in the pen body; the labor-saving assembly comprises a first wedge-shaped block fixedly connected to the top of the push rod, a transmission sliding groove formed in the inner side of the pen body, a transmission sliding block slidably connected to the interior of the transmission sliding groove, a transmission rolling wheel rotationally connected to one end of the transmission sliding block and a second wedge-shaped block arranged in the pen body and capable of vertically moving. According to the invention, the inclined surfaces of the 60-degree wedge-shaped block I and the 30-degree wedge-shaped block II are matched, and the force conduction of the transmission roller is combined, so that the vertical thrust of the injection driving mechanism is amplified into horizontal thrust, the operation force is reduced by more than 70%, the thrust in the whole injection process is ensured to be stable, and pains and errors are relieved.

The invention discloses a BimBH3 analogue containing D-type amino acid and N-terminal fatty acid acylation, a preparation method of the BimBH3 analogue and application of the BimBH3 analogue as a PTPN1 inhibitor to development of hypoglycemic drugs. The structural general formula of the novel BimBH3 mimic peptide analogue is shown as a formula I: # imgabs0 #, wherein Raa2 is equal to D-His, D-Leu, D-Pro, D-Ser, D-Arg, D-Gln, D-Lys, D-Trp, D-Val, D-Tyr, D-Ala, Raa3 is equal to D-Gln, Raa7 is equal to D-Arg, and Raa8 is equal to D-Allo-Ile. The mimic peptide compound is derived from a core region of a Bim-BH3 structural domain, different D-type amino acid site-specific replacement modification and N-terminal conjugated hexadecanoic acid modification are adopted for amino acids at the second, third, seventh and eighth sites respectively, the BimBH3 mimic peptide modified by the D-type amino acid is more stable and has higher metabolic stability, and the target binding capacity and inhibitory activity of the BimBH3 mimic peptide can still be reserved or even improved. The BimBH3 mimic peptide compound shows an excellent PTPN1 inhibitor, the ability of resisting protease hydrolase and various digestive enzymes is also remarkably improved, and the BimBH3 mimic peptide compound has longer pharmacological action time and can play a potential long-acting hypoglycemic role through subcutaneous injection or oral administration. The compound is completely prepared by a polypeptide solid-phase synthesis method, and an obtained crude product is subjected to semi-preparative liquid chromatography purification and freeze-drying to obtain a target compound.

The invention provides a sustained-release microneedle for treating ill-conditioned pregnancy and a preparation method and application thereof, and relates to the technical field of biological medicines.The sustained-release microneedle for treating ill-conditioned pregnancy comprises a base and a needle tip on the base, the needle tip part of the gel microneedle is made of heparin medicine, and the needle tip part of the gel microneedle is made of gelatin. The heparin medicine comprises heparin, heparin sodium, low-molecular heparin, low-molecular heparin sodium or low-molecular heparin calcium; the needle point part comprises a heparin photo-crosslinking monomer, and the base comprises a biocompatible polymer matrix. The sustained-release microneedle for treating pathological pregnancy provided by the embodiment of the invention has good mechanical strength, skin permeability and anticoagulant activity, can reduce skin bruises caused by subcutaneous injection of heparin, improves abortion caused by infection and inflammation and abortion caused by APS (anti-phospholipid antibody syndrome), can realize sustained release of drugs and increase of drug loading capacity, and has good application prospects. Sustainable drug delivery is achieved, and frequent injection is avoided.

The invention discloses a robot assisted diagnosis and treatment system for a nuclear medicine ward and an application method. The robot assisted diagnosis and treatment system comprises an AI robot for non-contact assisted diagnosis and treatment; the robot library is arranged on the same layer of the nuclear medicine ward; the remote interaction platform is used for issuing related instructions and man-machine interaction to the AI robot; a radiation protection and monitoring module, an identity recognition module, a health propaganda and education module, a ferry module, a visual doctor-patient communication module, a communication module, an RFID access control module and an environment disinfection module are integrated on the AI robot; the AI robot is connected with an external subcutaneous injection module, an external intravenous injection module, an external medicine distribution module and an external living goods conveying module through corresponding switching assemblies. According to the robot-assisted diagnosis and treatment system for the nuclear medicine ward and the application method, a semi-autonomous and remote interaction mode is used for replacing medical staff to execute face-to-face diagnosis and treatment behaviors with patients, and non-contact diagnosis and treatment are achieved through human-machine-patient high cooperation in the whole diagnosis and treatment process.

The present invention relates to a highly concentrated, stable pharmaceutical formulation of a pharmaceutically active anti-HER2 antibody, such as e.g. Trastuzumab (HERCEPTIN™), Pertuzumab or T-DM1, or a mixture of such antibody molecules for subcutaneous injection. In particular, the present invention relates to formulations comprising, in addition to a suitable amount of the anti-HER2 antibody, an effective amount of at least one hyaluronidase enzyme as a combined formulation or for use in form of a co-formulation. The formulations comprise additionally at least one buffering agent, such as e.g. a histidine buffer, a stabilizer or a mixture of two or more stabilizers (e.g. a saccharide, such as e.g. α,α-trehalose dihydrate or sucrose, and optionally methionine as a second stabilizer), a nonionic surfactant and an effective amount of at least one hyaluronidase enzyme. Methods for preparing such formulations and their uses thereof are also provided.

The present invention relates to a highly concentrated, stable pharmaceutical formulation of a pharmaceutically active anti-HER2 antibody, such as e.g. Trastuzumab (HERCEPTIN™), Pertuzumab or T-DM1, or a mixture of such antibody molecules for subcutaneous injection. In particular, the present invention relates to formulations comprising, in addition to a suitable amount of the anti-HER2 antibody, an effective amount of at least one hyaluronidase enzyme as a combined formulation or for use in form of a co-formulation. The formulations comprise additionally at least one buffering agent, such as e.g. a histidine buffer, a stabilizer or a mixture of two or more stabilizers (e.g. a saccharide, such as e.g. α,α-trehalose dihydrate or sucrose, and optionally methionine as a second stabilizer), a nonionic surfactant and an effective amount of at least one hyaluronidase enzyme. Methods for preparing such formulations and their uses thereof are also provided.

The present disclosure provides a new PH20 mutant enzyme which shows significantly enhanced aggregation stability, can be used for the development of drug subcutaneous injection preparations, facilitates the diffusion of drugs in subcutaneous tissues, reduces subcutaneous administration volume limitations, and alleviates swelling or pain caused by large-volume subcutaneous injection.

The invention provides a multifunctional self-bionic nano vaccine for treating breast cancer. The multifunctional self-bionic nano vaccine comprises MnOx nano particles serving as inner cores and fusion cell membranes wrapping the surfaces of the inner cores of the MnOx nano particles, the fused cell membrane is obtained by fusing a remodeled 4T1 cell membrane and a remodeled DC cell membrane. According to the invention, the nano vaccine can play an immunotherapy role in treating breast cancer under the condition of subcutaneous injection. After subcutaneous peritumoral injection, the multifunctional autologous bionic nano vaccine can target tumor tissues to play an in-situ chemical power treatment role, chemotactic to drainage lymph nodes to realize efficient T cell immune response to play an immunotherapy role, and main organs of the whole body are less gathered, so that the vaccine is safe and reliable; the SPNE prepared in the prior art can cause a certain liver aggregation effect after intravenous injection, and great toxic and side effects are generated.

The present invention relates to the treatment of subjects having CD20-positive cell proliferative disorders (e.g., B cell proliferative disorders, such as non-Hodgkin's lymphomas or chronic lymphocytic leukemia). More specifically, the invention pertains to the treatment of subjects having a B cell proliferative disorder by subcutaneous administration of mosunetuzumab as a monotherapy or in combination with lenalidomide.

The present invention relates to a pre-assembled reconstitution and injection device, comprising an injection section having a cartridge for holding a diluent or drug product and a reconstitution section having a vial for holding a drug, whereby the injection section may only be disassembled from the reconstitution section after activation of the device has occurred. In an embodiment for use with a pen needle, the reconstitution section comprises a vial needle hub having a reconstitution needle for piercing both the vial and cartridge. In an embodiment of the invention for use with a hypodermic needle, the injection section comprises a cartridge needle hub with a cartridge needle and male luer connection having threads for securing a hypodermic needle, and the reconstitution section comprises a needle hub with a vial needle and a female luer connection for engagement with the male luer connection.

The utility model relates to a universal type ejection needle assisting device for muscle or subcutaneous injection, which comprises a shell, a base matched with the shell and used for containing a puncture assembly, a clamping device located in the shell and capable of moving up and down relative to the shell and an ejection device located between the shell and the clamping device, and the clamping device is used for clamping the puncture assembly. The structure of the puncture needle is changed, after the puncture needle and the injection soft needle are ejected and pricked into the body of a patient, the puncture needle can be taken out by the ejection clamping device, then the puncture needle is placed into the base again, and waste treatment is carried out along with the base. Meanwhile, the clamping disc capable of clamping the infusion tube and the infusion needle head is arranged and matched with the soft needle base of the injection soft needle, so that the insulin pump injection needle is suitable for injection of an insulin pump and an insulin pen, and the universality is high.

The invention relates to the technical field of medicines, foods and health-care products, in particular to application of morusin in preparation of a product for treating osteoarthritis. A hydrogen peroxide induced chondrocyte in-vitro model and a D-galactose subcutaneous injection osteoarthritis animal model are used for screening and evaluating the morusin, and it is found that the morusin has the obvious effects of relieving articular cartilage injury, enhancing articular cartilage toughness, delaying the course of osteoarthritis and the like. Wide application prospects are realized in the aspect of preparing products for treating osteoarthritis.

The present invention relates to a highly concentrated, stable pharmaceutical formulation of a pharmaceutically active anti-CD20 antibody, such as e.g. Rituximab, Ocrelizumab, or HuMab<CD20>, or a mixture of such antibody molecules for subcutaneous injection. In particular, the present invention relates to formulations comprising, in addition to a suitable amount of the anti-CD20 antibody, an effective amount of at least one hyaluronidase enzyme as a combined formulation or for use in form of a co-formulation. The said formulations comprise additionally at least one buffering agent, such as e.g. a histidine buffer, a stabilizer or a mixture of two or more stabilizers (e.g. a saccharide, such as e.g. α,α-trehalose dihydrate or sucrose, and optionally methionine as a second stabilizer), a nonionic surfactant and an effective amount of at least one hyaluronidase enzyme. Methods for preparing such formulations and their uses thereof are also provided.

The invention discloses a programmable multi-modified long-acting slow-release elastin-like protein (ELP) vector and an application thereof. A programmable biosynthesis method is utilized to construct a series of ELPs with different structures and properties consisting of different amino acids, including a composite characteristic positive charge series ELP (IVK), a composite characteristic negative charge series ELP (IVE), a composite characteristic benzene ring series ELP (IVF), a composite characteristic hydroxyl benzene ring series ELP (IVY) and a structure chimeric characteristic series ELP (IVYIVE). After subcutaneous injection, the ELP carrier is subjected to in-situ phase change under the triggering of body temperature and forms a drug reservoir, and the drug is slowly released from the reservoir to an in-vivo circulatory system, so that the effective action time of single injection of the drug is remarkably prolonged, pharmacokinetic parameters are improved, and the compliance of a patient is improved. The programmable slow-release ELP has wide application potential and is suitable for delivery of various drugs such as proteins, nucleic acids, polypeptides, antibodies and small molecule drugs.

The invention relates to the technical field of pharmaceutical preparations, and discloses a high-drug-loading risperidone sustained release microsphere for subcutaneous injection and a preparation method thereof, and the preparation method comprises the following steps: mixing risperidone, polylactic acid and dichloromethane to obtain an oil phase; dissolving a pore-forming agent in water to obtain a pore-forming agent solution; mixing polyvinyl alcohol, sodium chloride and water to obtain a water phase; mixing the oil phase with the pore-forming agent solution to obtain primary emulsion; mixing and stirring the primary emulsion and a water phase until dichloromethane is completely volatilized to obtain microspheres loaded with speridone; mixing cellulose acetate, polyethylene glycol and an organic solvent to obtain a coating solution; and coating the risperidone-loaded microspheres with a coating solution to obtain the high-drug-loading risperidone sustained-release microspheres capable of being used for subcutaneous injection. According to the invention, the efficient drug loading is realized, the injection comfort is improved, the slow permeation and release of the drug are realized, and the onset speed and the long-acting treatment demand are balanced.

The invention belongs to the technical field of medical experimental animal models, and particularly relates to a construction method of a rabbit ear acne model for studying acne pathogenesis and drug curative effect. A healthy New Zealand large-ear white rabbit is selected, a testosterone solution is subcutaneously injected to induce endocrine disorder, oleic acid is smeared at an opening of an external auditory canal on the inner side of an ear, dermatobacterium acnes suspension is subcutaneously injected, and whether acne-like lesions such as erythema, papule and comedo appear on the skin of the ear or not is observed. The method is easy and convenient to operate, low in cost, good in repeatability, capable of simulating the pathological process of human acne and suitable for acne pathogenesis research and drug screening.

One method for treating Crohn's disease in a patient involves administering a specific antibody against IL-23, for example, guselkumab, in an initial subcutaneous dose and subsequent subcutaneous doses so that the patient responds to the antibody and meets one or more of the clinical objectives.

The present invention relates to pharmaceutical compositions for intramuscular or subcutaneous injection administration comprising microparticles of the anti-TB compound bedaquiline suspended in a pharmaceutically acceptable aqueous carrier, and to the use of such pharmaceutical compositions in the treatment and prevention of pathogenic mycobacterial infections.

The present invention provides methods of using non-naturally occurring melanocortin analogs to increase body weight and / or increase food consumption in a subject having a kidney disease and / or a liver disease (e.g., chronic kidney disease, renal failure, non-alcoholic fatty liver disease (NAFLD)). Also provided are methods of stimulating appetite in a subject via administration of a non-naturally occurring melanocortin analogue. The non-naturally occurring melanocortin analogs may be present in pharmaceutical compositions and delivered via parenteral administration (e.g., subcutaneous injection). The methods improve appetite, increase food consumption, increase body weight, muscle mass, and / or fat mass in the subject.

Provided in the present disclosure are materials, devices, systems, and methods for performing cryo-surgery in a mammalian subject. More particularly, presented are a slurry, devices, systems, and methods for subcutaneously injecting the slurry into a patient in need of bodyfat reduction intervention. The slurry, devices, systems, and methods permit highly efficacious subcutaneous ice phase-change lipolysis while not requiring that the patient be placed under general anesthesia, nor requiring significant new surgical training among practitioners.

FGFR3 gain-of-function mutations are responsible for a family of chondrodysplasias namely, achondroplasia (ACH) the most common form of dwarfism, a lethal form of dwarfism thanatophoric dysplasia (TD) as well as and hypochondroplasia. Recent data demonstrate that Infigratinib (NVP-BGJ398) corrects pathological hallmarks of ACH and support it as a potential therapeutic approach for FGFR3-related skeletal diseases. Now the inventors has investigated the feasibility to treat the defective growth of the skeleton during the pregnancy with the drug. They treated pregnant female Fgfr3Neo / Y367C mice with the drug (4 mg / kg) that was injected subcutaneously at day E14.5 continuing daily through day 1 (after birth). The data indicated that BGJ398 treatment during 5 days in pregnant mice successfully repressed skeletal anomalies that occurred during embryonic stages. Accordingly, the present invention relates to methods for treatment of FGFR3-related skeletal diseases during pregnancy with Infigratinib.

Provided herein are methods of treating a subject having a CD20 - positive cell-proliferative disorder (e.g., a B-cell proliferative disorder, e.g., non-Hodgkin's lymphoma or chronic lymphocytic leukaemia).SOLUTION: The present invention provides the treatment of a subject having a B-cell proliferative disorder by subcutaneous administration of mosnetuzumab as monotherapy or in combination with lenalidomide.SELECTED DRAWING: Figure 10

The utility model relates to the technical field of medical instruments, and discloses a hypodermic injection positioning card which comprises a card body, an injection area and a positioning area are divided on the card body, a plurality of injection holes are formed in the injection area, the positioning area is arranged in the center of the injection area, and the positioning area is of a through hole structure. An injection date identifier and a serial number identifier are also arranged in the injection area; the injection area is divided on the card body, the injection hole is formed in the injection area, and the injection date mark and the serial number mark are arranged, so that when the injection card is used, a nurse can know the date and the position for injection by observing the time mark and the serial number mark in the injection area, and meanwhile, the injection time is greatly shortened. Nursing personnel can quickly deduce the specific part of the last injection of a patient by observing the injection date mark and the serial number mark in the injection area and combining the actual date, and compared with the prior art, the injection device has the advantages that injection work is convenient to carry out, and the time needed by injection is shortened.

The invention relates to a cell membrane bionic drug-loaded carbon dot nano-material as well as a preparation method and application thereof. The nano-composite is prepared by the following steps: preparing carbon dots, cross-linking to form a reduction responsive carbon dot nano-cluster, sequentially loading chemotherapeutic drugs and coating a cancer cell membrane to form a nano-vaccine. After the nano vaccine is injected into the body of a mouse through caudal vein, the enrichment of the nano vaccine in a tumor part can be enhanced by utilizing the active tumor targeting characteristic of a cancer cell membrane, and tumor cells can be induced to generate immunogenic death through carried chemotherapy drugs and photothermal therapy, so that chemotherapy / photothermal / immune combined therapy on tumors is realized; the obvious anti-tumor effect is realized. In addition, as a nano vaccine, after subcutaneous injection, the nano vaccine can also utilize the tumor antigen carried by a cancer cell membrane and the adjuvant characteristics of the carbon dots to activate the anti-tumor immunity of an organism so as to prevent tumors, and has potential clinical application value.

To provide an injection device for subcutaneous administration, for preventing cardiovascular events in a human subject.SOLUTION: The present invention provides an injection device for subcutaneous administration, comprising a fixed dose of 275 mg to 325 mg of an interfering ribonucleic acid (RNAi) agent. The device comprises a double-stranded ribonucleic acid comprising a sense strand and an antisense strand forming a double-stranded region, where the antisense strand comprises the nucleotide sequence of 5'-asCfsaAfAfAfgCfaAfaAfcAfgGfuCfuagsasa-3' (SEQ ID NO: 3), and the sense strand comprises the nucleotide sequence of 5'-csusagacCfuGfudTuugcuuuugu-3' (SEQ ID NO: 4), where a, g, c and u are 2'-O-methyl (2'-OMe) A, G, C, or U; Af, Gf, Cf or Uf are 2'-fluoro A, G, C or U; dT is 2'-deoxythymidine; and s is a phosphorothioate linkage.SELECTED DRAWING: None

The invention discloses a construction method of an endothelial cell knockout Cdc42 gene aggravated bleomycin induced pulmonary fibrosis mouse model, which comprises the following steps of: mating a Cdc42 gene conditional knockout mouse with a mouse (Tie2-CreER) of which the endothelial cell specifically expresses tamoxifen induced Cre recombinase to obtain a double-transgenic mouse (Cdc42fl / fl-Tie2-CreER); the Cdc42 gene is specifically knocked out in vascular endothelial cells under the induction of tamoxifen, and then pulmonary fibrosis is induced by subcutaneous injection of bleomycin. The model shows aggravated pulmonary fibrosis phenotypes, including collagen deposition increase, alveolar structure damage and fibrosis-related protein expression up-regulation, and is high in construction success rate and good in repeatability. The invention also provides an application of the model in research of systemic sclerosis related interstitial lung disease pathogenesis and screening of anti-pulmonary fibrosis drugs, and an application of the Cdc42 gene as a drug target, and provides an accurate and reliable tool for pulmonary fibrosis research.

A Hypodermic Needle Safety Guard intended for sharps prevention and safer hypodermic needle use during all stages of an injection process. The Safety Guard may include two symmetrically positioned multi-featured arms that include spring tension, multiple hinges and needle locks. These arms may connect a proximal Luer body and a distal alignment tip thereby enabling the guard to open, close and lock on a needle when manual pressure is applied. The Guard position during hypodermic needle use tends to prevent sharps injury by adjusting the exposure of the Needle tip.

The present application belongs to the technical field of biomedicine, and relates to an in vivo self-assembling system targeting the central nervous system for treating diabetes. The present application provides an in vivo self-assembling system targeting the central nervous system. The in vivo self-assembling system targeting the central nervous system is a recombinant plasmid expressing a nucleic acid molecule, wherein the nucleic acid molecule encodes a fibroblast growth factor-based fusion protein, and the fibroblast growth factor-based fusion protein comprises a propeptide, a peptide targeting the central nervous system, a linker peptide, and a fibroblast growth factor variant having an amino acid sequence as set forth in SEQ ID NO.1, which are sequentially linked. The in vivo self-assembling system targeting the central nervous system can cross the blood-brain barrier and specifically reach the central nervous system via routes other than intracranial injection, such as subcutaneous injection and intravenous injection. The system exerts a long-lasting blood glucose-lowering effect, without causing adverse reactions, thereby retaining the anti-diabetic activity of fibroblast growth factors and avoiding the tumorigenic risks thereof.